FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer

被引：0
|
作者：
Shao Zhimin
Fan, Lei
Ma Linxiaoxi
Wu, Songyang
Chen, Li
Liu, Xiyu
Zhang, Wenjuan
Hu, Xin
Jiang, Yizhou
Wang, Zhonghua
Li, Huajun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[4] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
    Haiderali, Amin
    Huang, Min
    Pan, Wilbur
    Akers, Katherine G.
    Maciel, Dylan
    Frederickson, Andrew M.
    FUTURE ONCOLOGY, 2024, 20 (22) : 1587 - 1600
  • [22] First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
    Liu, Minetta C.
    Janni, Wolfgang
    Georgoulias, Vassilis
    Yardley, Denise A.
    Harbeck, Nadia
    Wei, Xin
    McGovern, Desmond
    Beck, Robert
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10427 - 10433
  • [23] Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Schmid, P.
    McArthur, H. L.
    Cortes, J.
    Xu, B.
    Cardoso, F.
    Casalnuovo, M. L.
    Demirci, U.
    Freitas, R., Jr.
    Ghosh, J.
    Hegg, R.
    Iwata, H.
    Chuken, Y. A. Lopez
    Nechaeva, M.
    Robson, M. E.
    Villalobos Valencia, R.
    Lloyd, A.
    D'Cruz, C.
    Foxley, A.
    Park, Y. H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1212 - 1213
  • [24] Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.
    Wang, Z.
    Hu, X.
    Wang, B.
    Wang, L.
    Zhang, J.
    Wang, H.
    Liu, G.
    Hu, Z.
    Wu, J.
    Shao, Z.
    CANCER RESEARCH, 2011, 71
  • [25] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
    Cortes Salgado, A.
    Perez Garcia, J. M.
    Cortez Castedo, S. P.
    Gion Cortes, M.
    Morales Murillo, S.
    Blancas Lopez-Barajas, I.
    Blanch, S.
    Calvo Plaza, I.
    Diaz Fernandez, N.
    Marme, F.
    Martinez Bueno, A.
    Taberner Bonastre, M. T.
    De laurentiis, M.
    Ruiz Borrego, M.
    Schmid, P.
    Guarneri, V.
    Gligorov, J.
    Sampayo-Cordero, M.
    Llombart Cussac, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
  • [26] Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study
    Liao, Yuqian
    Fan, Ying
    Wan, Yiye
    Li, Jun
    Peng, Lixiang
    CHEMOTHERAPY, 2013, 59 (03) : 207 - 213
  • [27] Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
    Yi-Zhou Jiang
    Yin Liu
    Yi Xiao
    Xin Hu
    Lin Jiang
    Wen-Jia Zuo
    Ding Ma
    Jiahan Ding
    Xiaoyu Zhu
    Jianjun Zou
    Claire Verschraegen
    Daniel G. Stover
    Virginia Kaklamani
    Zhong-Hua Wang
    Zhi-Ming Shao
    Cell Research, 2021, 31 : 178 - 186
  • [28] First-line Option for metastatic triple-negative Breast Cancer Live longer with new Immunotherapeutic Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 69 - 69
  • [29] Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
    Jiang, Yi-Zhou
    Liu, Yin
    Xiao, Yi
    Hu, Xin
    Jiang, Lin
    Zuo, Wen-Jia
    Ma, Ding
    Ding, Jiahan
    Zhu, Xiaoyu
    Zou, Jianjun
    Verschraegen, Claire
    Stover, Daniel G.
    Kaklamani, Virginia
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CELL RESEARCH, 2021, 31 (02) : 178 - 186
  • [30] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
    Gong, Chengcheng
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Zhang, Sheng
    Tao, Zhonghua
    Li, Ting
    Zhao, Yannan
    Li, Yi
    Wang, Biyun
    Hu, Xichun
    CANCER RESEARCH, 2018, 78 (04)
12345